Close Menu

Cancer

The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.

The drugmaker will present data from the Impower110 trial at an upcoming meeting and submit the data to regulatory authorities.

The Canadian company said its technology platform allows it to match patients to cancer treatments more efficiently and to identify novel patient populations.

As labs implement TMB workflows in-house, studies are showing that its is possible to validate assays with cutoff points remaining stable across complex clinical cohorts and in different drug contexts.

Although the FDA has already approved the regimen in this indication after seeing its impact on progression-free survival, the latest data speaks to its impact on survival. 

The companies will use their respective technologies to identify inhibitors of cancer-associated gene targets and optimize their use as therapeutics.

Oct
03

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
23

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.